July 09, 2025
The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and bone-related metastases.
July 08, 2025
July 07, 2025
July 05, 2025
July 04, 2025
November 3rd 2023
By Skylar Jeremias
Here are the top 5 biosimilar articles for the week of October 30, 2023.
November 2nd 2023
An international survey found that providers agree that use of biosimilars in inflammatory bowel disease (IBD) is safe and effective in both patients who are treatment-naïve and those who are already being treated with a reference agent.
November 1st 2023
The FDA approved Amgen’s Wezlana (ustekinumab-auub) as the first biosimilar to reference Stelara (ustekinumab). The biosimilar was also approved with an interchangeability designation.
Between 3 regulatory approvals, 2 complete response letters, and new data and industry insights, October brought a number of business updates that have the potential to impact the entire US biosimilar industry.
October 31st 2023
Providers speak to the importance of being knowledgeable of efficacy and safety data before prescribing biosimilars to patients.
Clinical and social challenges associated with biosimilars are discussed by key opinion leaders.
A recent study found that a pegfilgrastim biosimilar was effective against chemotherapy-induced neutropenia and had comparable safety and efficacy profiles compared with the originator (Neulasta) in patients with breast cancer.
October 30th 2023
By Ivo Abraham, PhD
In his comeback column, Ivo Abraham, PhD, chief scientist of Matrix45 and a professor at the University of Arizona, explores the world of biobetters and the complicated dynamics surrounding the FDA approval of Zymfentra, the first subcutaneous infliximab.
October 29th 2023
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, reflects on data concerning the potential for adalimumab biosimilars to gain significant market share.
October 28th 2023
A poster from AMCP Nexus quantifies trends in biosimilar coverage within Tufts Medical Center, finding that payer coverage of these products has increased but individual preferences among payers still vary.